Analysis of common adverse reactions of budesonide oral suspension (Eohilia)

Budesonide oral suspension (Eohilia), a novel topical glucocorticoid formulation, has shown promising anti-inflammatory effects in the treatment of eosinophilic esophagitis. However, like other glucocorticoid drugs, it may still cause certain adverse reactions during use, mainly related to its local immunosuppressive effect and systemic absorption. Eohilia’s adverse reactions can be divided into two categories: local and systemic. Local reactions mostly occur in the oral cavity and upper respiratory tract, such as oral candida infection, sore throat, hoarseness, dry mouth, etc. Since budesonide acts locally in the esophagus, some of the liquid may remain in the oropharynx. Therefore, patients are advised to avoid drinking or eating immediately after taking the drug, but they can rinse their mouth after 30 minutes to reduce the risk of oral fungal infection.

Systemic adverse reactions depend on the degree of drug absorption. AlthoughEohilia is designed for local treatment, some drugs are still absorbed into the bloodstream. Typical corticosteroid side effects may occur with long-term or high-dose use, such as weight gain, moon face, skin thinning, osteoporosis, mood swings, and sleep disorders. In some patients, adrenal suppression may also occur, manifested by fatigue, hypotension, or diminished stress response. In children and adolescents, potential growth retardation is a concern.

Another noteworthy adverse reaction is the interaction between the drug and other immunosuppressants. Combined use of Eohilia with CYP3A4 inhibitors (such as ketoconazole) may increase the blood concentration of budesonide, thereby enhancing systemic side effects; conversely, combined use with inducers may reduce the efficacy. Therefore, you should follow your doctor's advice when taking medications together and avoid adjusting the dosage on your own.

Reference materials:https://www.drugs.com